Kidney transplant study compares immune effects of two common drugs
NCT ID NCT02894606
First seen Jun 09, 2026 · Last updated Jun 22, 2026 · Updated 3 times
Summary
This study looked at 49 kidney transplant patients to see how two different induction therapies—thymoglobulin and basiliximab—affect B cells, a type of immune cell. Researchers compared the B cell profiles between the two groups and with data from patients who had chronic antibody-mediated rejection. The goal was to better understand how these drugs influence the immune system after transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL TRANSPLANT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHU Brest
Brest, 29200, France
-
Tours University Hospital
Tours, 37000, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Thymoglobulin and basiliximab (induction therapies given before kidney transplant to prevent rejection)
What this could lead to
If successful, this could help doctors choose the best induction therapy for kidney transplant patients and reduce the risk of chronic rejection.
What could go wrong
This is a small, observational study that does not test a new treatment. It only looks at immune cell changes, so it may not lead to direct improvements in patient care.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.